Suppliers / Chongqing Daxin Pharmaceutical

Chongqing Daxin Pharmaceutical

China Updated 9 July 2026

Chongqing Daxin Pharmaceutical is an API manufacturer based in China. It holds 11 active US drug master files across a filed portfolio of 8 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 28 June 2024 as VAI.

11
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
2
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 28 June 2024 VAI US FDA
  • 11 May 2018 VAI US FDA
  • 29 January 2015 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3000291692

What they file, and where

Molecule Regulators Docs
Daptomycin US FDA 2
Lovastatin US FDA 2
Mycophenolic Acid US FDA 2
Mevastatin US FDA 1
Mycophenolate Mofetil US FDA 1
Sirolimus US FDA 1
Tobramycin US FDA 1
Vancomycin US FDA 1

Also appears on these molecule pages

Daptomycin API Lovastatin API Mycophenolate Mofetil API Mycophenolic Acid API Sirolimus API Tobramycin API Vancomycin API

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 2 None
US FDA None 1

Questions about Chongqing Daxin Pharmaceutical

Does Chongqing Daxin Pharmaceutical hold a US DMF or a CEP?
Chongqing Daxin Pharmaceutical holds 11 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Chongqing Daxin Pharmaceutical FDA-registered?
One site operated by Chongqing Daxin Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Chongqing Daxin Pharmaceutical's last inspection go?
The most recent inspection on record closed on 28 June 2024 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 3 inspections are on file.
Where does Chongqing Daxin Pharmaceutical manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Chongqing Daxin Pharmaceutical make?
8 molecules are on record against Chongqing Daxin Pharmaceutical, including Daptomycin, Lovastatin, Mycophenolic Acid and Mevastatin. Each links through to that molecule's full manufacturer list.
Which regulators recognise Chongqing Daxin Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Chongqing Daxin Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 28 June 2024.

Comparable suppliers

Concord Biotech shares 5 molecules Livzon Group Fuzhou Fuxing Pharmaceutical shares 4 molecules Biocon shares 3 molecules Apotex shares 3 molecules Chunghwa Chemical Synthesis & Biotech shares 3 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates